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COL4A5 gene deletion and production of post-transplant anti-a3(IV)
collagen alloantibodies in Alport syndrome. Mutations in the COL4A5
gene encoding the aS(IV) chain of type IV collagen have been impli-
cated as the primary defect in X-linked Alport syndrome. Several kinds
of mutations have been reported so far, spanning point mutations to
complete gene deletions. About 5% of Alport patients, who undergo
renal transplantation, develop anti-glomerular basement membrane
(GBM) nephritis, causing loss of allogralt function. In one such patient,
COL4A5 gene deletion was recently identified. In the present study, the
GBM constituent, targeted by the anti-GBM alloantibodies from the
patient who had complete COL4A5 gene deletion was identified. Its
identity was determined on the basis of circulating antibody binding to
various GBM constituents, domains of bovine type IV collagen and
recombinant NC1 domain of human type IV collagen. These results
establish, for the first time, the absence of the a5(IV) chain in Alport
GBM and, in the same patient, the production of an alloantibody that is
targeted to a different chain of type IV collagen, the a3(IV) chain. These
findings provide further support for the hypothesis that: (1) anti-a3(IV)
collagen alloantibodies mediate the allograft glomerulonephritis; and (2)
COL4A5 gene mutations cause defective assembly of the a3(IV) chain
in Alport GBM, as reflected by the production of anti-a3(IV) alloanti-
bodies.
Alport syndrome is an heritable disorder which is character-
ized by sensorineural deafness and hematuria with relentless
progression to end-stage renal disease [1—3]. The renal lesion is
characterized by ultrastructural abnormalities (thinning, thick-
ening, diffuse splitting and multilaminations of the lamina
densa) in the glomerular basement membrane (GBM). Muta-
tions in the COL4A5 gene encoding the aS(IV) chain of type IV
collagen have been implicated as the primary defect in the
X-linked form of the disease [4—15]. The COL4AS gene is
located at the Alport locus, Xq22, and this gene has been shown
to be deleted [9], point mutated [10—14], or duplicated [15] in
several Alport families. How these mutations alter the structure
of type IV collagen remains undefined. In normal GBM this
collagen is composed of family of five known chains, alto aS
[4, 5, 12, 16—20], and may contain the newly discovered a6
chain [21].
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Defective incorporation of the a3(IV) chain into Alport GBM
has been implicated on the basis of three lines of evidence.
First, the binding of Goodpasture autoantibodies to Alport
GBM is frequently absent [22—26] and the binding of a mono-
clonal antibody directed against the Goodpasture autoantigen is
absent or diminished in several Alport patients, as determined
by immunofluoresence of tissue sections [27, 28]. These results
indicate the absence of the a3(IV) chain, as this chain has now
been identified as the target for these antibodies [29]. Second, a
collagenase resistant component, M28 +, which corresponds
to the NC1 domain of the a3(IV) chain is absent from the GBM
of three Alport patients, indicating the absence of a3(IV) chain
[30—32]. Third, the alloantibodies from six Alport patients are
targeted to the NC1 domain of type IV collagen [26, 27, 29, 33,
34], three of which have been shown to be targeted to the
a3(IV) chain, and the alloantibodies do not bind to Alport GBM
[29]. The production of the post-transplant anti-a3(IV) alloanti-
bodies suggests that an alteration occurs in type IV collagen of
Alport GBM in which incorporation of molecules containing the
a3(IV) chain is defective (that is, the chain is absent or an
epitope is altered or masked) [29]. Together, the three lines of
evidence strongly indicate defective assembly of the a3(IV)
chain in Alport GBM.
Defective assembly of the a3(IV) chain raises a dichotomy
given that the primary defect involves mutation in a separate
chain, the a5(IV) chain. The conundrum leads to the hypothesis
that a mechanism exists for the synthesis of normal GBM that
links the assembly of triple-helical molecules containing the aS
chain with triple-helical molecules containing the a3 chain [29,
35]. The hypothesis is based on the assumption that the
COL4A5 gene defects occur in all the patients on which the
conundrum is based (vide supra); however, the gene defect has
not been determined in any of the cases. Conceivably, certain
patients could harbor the non-X-linked form of the Alport
syndrome which could be caused by an a3 gene defect. In such
cases, the conundrum would be negated. Likewise, the produc-
tion of post-transplant anti-a3 alloantibodies could be explained
simply by an a3 gene defect, and thus, negate the inference
made from the alloantibody target [29] that a mechanism exists
linking the assembly of the a5 and a3 chain in normal GBM.
Therefore, the present study was undertaken to determine
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whether an aS gene defect coexists with production of post-
transplant anti-a3 chain alloantibodies. The results establish,
for the first time, a COL4A5 gene deletion causing complete
loss of the a5 chain and, in the same patient, the production of
an alloantibody that is targeted to a different chain, the a3(IV)
chain. The findings strengthen the hypothesis that a mechanism
exists that links the assembly of the a5 and a3 chain of type IV
collagen in normal GBM.
Methods
Materials
Basement membrane components, bovine type IV collagen
domains and NC! domains, recombinant human NC! domains
and common reagents have been described previously [16, 36,
37]. Alport alloantibodies were from a patient no. A-9!25, as
described elsewhere [9]. The patient case history is summarized
in [9].
Electrophoresis and ELISA techniques
One and two dimensional gel electrophoresis and immuno-
blotting, and ELISA measurements were performed as previ-
ously described [161. The dilution of Alport alloantibodies used
in the present study was 1:50.
Results
Experimental approach
The GBM constituents, a chains from bovine NC! domain
and recombinant human NC! domains of type IV collagen,
were used to address the target for circulating anti-GBM
alloantibodies from an Alport patient with complete COL4A5
gene deletion. The target for the alloantibodies was identified by
enzyme linked immunosorbent assay (ELISA), HPLC chroma-
tography, one and two dimensional electrophoresis and immu-
noblotting.
IdentUlcation of GBM constituent/s that bind A/port
alloantibodies
The binding of Alport alloantibodies to various basement
membrane constituents and collagen IV domains was deter-
mined by direct ELISA measurement (Fig. 1). The alloantibod-
ies bound specifically to the NC! domain collagen IV with
essentially no binding to other components, that is, fibronectin,
laminin, heparan sulfate proteoglycan, entactin, 7S domain of
collagen IV or triple helical fragments from pepsin digestion of
bovine GBM. The control sera did not bind any of these
constituents (Fig. 1).
Identification of bovine aNCJ chains that bind A/port
alloantibodies
The binding of the alloantibodies to the NC1 domain (hex-
amer) of collagen IV was further investigated by immunoblot
analysis of NC! hexamer resolved by one dimensional gel
electrophoresis (Fig. 2A, lane 2). The major binding was
observed with the dimeric subunits (D) as reported previously
for three other alloantibodies [16]. As a reference, NC! hex-
amer resolved by gel electrophoresis and stained with silver is
also shown (Fig. 2A lane 1). At the monomer level (M), the
alloantibodies bound to two bands of molecular weight 28 kDa
and 26/27 kDa. The 28 kDa band was previously identified as
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Fig. I. 1dentfication of GBM constituent(s) that bind A/port alloanti-
bodies. The various basement membrane components were: F, fi-
bronectin; L, laminin; HSP, heparan sulfate proteoglycan; E, entactin;
7S, 7S domain collagen IV; TH, triple-helical domain (pepsin frag-
ments); NC!, non-collagenous domain of collagen IV. The dilution of
alloantibodies (R) and control () serum was 1:50.
the NC! domain of a3 chain of type IV co!lagen [19, 38, 39].
The second band of 26/27 kDa may represent the truncated form
of 28 kDa NC1 monomer of a3 chain, resulting from a different
cleavage sites for bacterial collagenase within the triple helix-
NC1 junction region [38].
To identify the a chain origin of NC 1 domain-bound alloanti-
bodies, the monomeric aNC1 domains were resolved by one
dimensional gel electrophoresis and analyzed by subsequent
immunoblotting using Alport alloantibodies (Fig. 2B). The
alloantibodies specifically bound to a3(IV)NC1 monomer.
To identify the target of the a chain origin of dimeric NC!
domains that bind alloantibodies (Fig. 2A, lane 1), the
al+a2NCl dimeric and cs3-a5NC1 dimeric fractions were
analyzed by two-dimensional gel electrophoresis and subse-
quent immunoblotting (Fig. 2C, D). The alloantibodies primar-
ily bound to a3 containing dimers (Fig. 2D) with minimal
binding with al+a2NCl dimeric fraction (Fig. 2C). The identity
of the numbered spots in the panel D corresponded mainly to
the a3NCI homodimers as previously described [16, 29]. These
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Fig. 2. Identification of bovine aNd domains that bind the Alport alloantibodies. Bovine NC! domains were prepared as described earlier [16,
39]. A. Analysis of NC! domain (hexamer). The pattern in lane I was visualized by silver staining and pattern in lane 2 was analysed by
immunoblotting with alloantibodies. The alloantibodies bound to the dimeric components and two monomeric components. B. The immunoblot
analysis of the bovine NC 1 monomers. The alloantibodies bound to a3NC 1 monomers, and no reactivity was observed to a! + a2NC1 and a4NC 1
monomers. C and D. The two dimensional electrophoresis and immunoblotting analysis of the a! + a2NC1 dimers and a3 +a4+a5NC 1 dimers,
respectively. The alloantibodies bound mainly to the a3NCI dimers. The identity of a3NCI dimers as the target was determined by comparing the
components that react with alloantibodies with their chain identity that was previously established by N-terminal amino acid sequence analysis [16,
29]. Components 16, 18, 20, 21 and 22 represent a3NCl homodimers, component 14 represents a3NC1 and a4NC1 containing dimers and
component 24 and 25 represent a3 and a5NC1 containing homo- or heterodimer [16, 29]. The p1 of dimeric components in two dimensional analysis
were between 6.8 and 8.4. The molecular weight of the dimeric fraction was around 54 kDa.
results establish the target for alloantibodies as the a3 dimers
and monomers, but do not rule out aS NC! domain as a target,
because aS dimers and a3 dimers comigrate at positions 24 and
25, as previously described [16, 29].
Identification of recombinant human NCJ domain(s) that
bind to Alport alloantibodies
Recombinant human NC 1 domains were used to address the
specificity of Alport alloantibodies to human aNC I domains
and because of the availability of aSNC1 domain for analysis.
The recombinant NC! domains were previously characterized
and shown to bind various anti-synthetic peptide antibodies
[36]. The recombinant NC! domains of al, a2, a3, a4 and aS
chains were resolved by gel electrophoresis and subsequently
analyzed by immunoblotting against the alloantibodies. The
alloantibodies specifically bound to the a3(IV)NC 1 domain with
minimal binding to any other recombinant NC! proteins (Fig.
3). These results unequivocally establish the target for the
Alport alloantibodies as the a3 chain of collagen IV.
Discussion
In the present study, the GBM constituent, targeted by the
anti-GBM alloantibodies from a patient who had complete
COL4AS gene deletion was identified. Its identity, the a3(IV)
chain of type IV collagen, was established on the basis of
circulating antibody binding to various GBM constituents,
domains of bovine type IV collagen, and recombinant NC!
domain of human type IV collagen. However, the occurrence of
an alloantibody targeted to aS(IV) chain cannot be fully ex-
cluded because: (1) some binding was observed in NC! dimers
that may contain aS(IV)NC1 domain; conceivably, the normal
configuration of aS(IV) chain in specialized basement mem-
brane is a privilaged site not available for detection by surveil-
ling lymphocytes; and (2) the a5(IV) antibody could be bound to
the allograft. The present findings extend the number of Alport
patients to four who developed a3(IV) alloantibody after trans-
Fig. 3. Identification of recombinant human aNCI domain(s) that bind
Alport alloantibodies. The recombinant NC1-fusion proteins (a! to a5)
were resolved by gel electrophoresis and immunoblotted with Alport
alloantibodies. The alloantibodies bound specifically to the recombinant
a3NC1 domain. Molecular weight standards are present in lane S.
plantation [29], suggesting that this alloantibody mediates the
anti-GBM nephritis and loss of allograft function. Potentially,
alloantibody to other kinds of collagen chains or other BM
constituents may occur depending on the nature of the gene
mutation. Thus, it is important to determine the alloantibody
specificity along with genetic defect in a number of such
patients.
The present results establish, for the first time, the absence of
the a5(IV) chain in Alport GBM and, in the same patient, the
production of an alloantibody that is targeted to a different
chain of type IV collagen, the a3(IV) chain. This finding adds to
the growing body of circumstantial evidence (vide supra) that
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Fig. 4. Schematic illustration of molecular mechanisms leading to defective assembly of a5(IV) and a3(IV) chain of type IV collagen in Alport
GBM. A The assembly of a5(IV) into triple helical molecule (protomer) and dimerization of protomer through NC1-to-NC1 interaction, as it would
occur in a normal individual. In the patient with complete COL4A5 gene deletion, such a5(IV) containing protomers would not be formed. B A
mechanism that links the assembly of a5(IV) chain with the assembly of a3(IV) chain at the level of protomer formation; such interactions have
also been speculated by Kleppel et al [43, 44] and panel C at the level of supramolecular structure formation in normal GBM. A mutated a5 chain
or its complete deletion would cause defective assembly of the a3(IV) chain at the level of protomer formation (B) or supramolecular structure
formation (C). Black denotes a5(IV) chains and grey denotes a3(IV) chain in A and B, respectively, and a5(IV) containing protomer and a3(IV)
containing protomer, respectively in C.
COL4A5 mutations cause defective assembly of the a3 (IV)
chain in Alport GBM. This relationship implies the existence of
a mechanism for the synthesis of normal GBM which links the
assembly of triple-helical molecules containing the a3 (IV)
chain with triple-helical molecules containing the a5 chain.
Such a mechanism may occur at the level of protomer
formation or at the level of supramolecular structure. The
a5(IV) chain is presumed to be incorporated in triple helical
protomers that self associate forming supramolecular structures
(Fig. 4A), but in the case of the patient reported herein,
protomers containing the a5 (IV) chain are totally absent from
the GBM because of the complete COL4A5 gene deletion. The
a3(IV) and a5(IV) chains may normally be assembled to form
heterotnmers (triple-helical protomers) which in turn self-asso-
ciate forming suprastructures (Fig. 4B). Alternatively, a5(IV)-
containing protomers that do not contain a3(IV) chains may be
required for the incorporation of several a3(IV)-containing
protomers (Fig. 4C). Hence, mutations in the a5(IV) chain or
complete chain deletion could prevent the assembly of the
a3(IV) chain by either mechanism. Preliminary studies have
established the existence of a supramolecular complex in nor-
mal GBM that involves the a3, a4 and a5 chains of type IV
collagen [40]. How COL4A5 gene deletion affects the COL4A6
gene product remains to be analyzed.
The findings of the present study provide further evidence for
a molecular commonality in the pathogenesis of Alport post-
transplant anti-GBM nephritis and Goodpasture syndrome. The
occurrence of post-transplant anti-GBM nephritis in Alport
patients and Goodpasture syndrome is rare, and in both cases,
the pathogenic antibody causing renal failure is targeted to the
a3(IV) chain of basement membrane collagen [16, 19, 29, 37,
39]. Potentially, there may also be a commonality in the
etiology of the antibody production. In the few Alport patients
who develop alloantibodies after transplantation, the normal
allograft serves as both the immunogen and the target for the
alloantibodies, indicating that the patient was not self tolerant
to the a3(IV) chain. In Goodpasture syndrome genetic predis-
position associated with HLA-DR2 and exposure of a seques-
tered epitope on the a3(IV) chain are possibly involved in the
initiation of the autoantibody production [41, 42]. Thus, the
Alport patients who develop post-transplant anti-GBM nephri-
tis may represent individuals who otherwise are predisposed to
a clinical course of Goodpasture syndrome.
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